Exagen Inc. to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Exagen (Nasdaq: XGN) announced management will participate in two investor conferences in March 2026: a virtual KeyBank Capital Markets Healthcare Forum on March 17, 2026 (investor meetings and a fireside chat at 3:00 p.m. ET) and the Roth Capital Conference in Laguna Niguel on March 23, 2026 (investor meetings).

News Market Reaction – XGN

-3.38%

3 alerts

-3.38% Session close to close

$85.67M Market Cap

0.6x Rel. Volume

In the Mar 3 session, XGN declined 3.38%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences:

KeyBank Capital Markets Healthcare Forum - Virtual

Date: March 17, 2026

Participation: Investor meetings and fireside chat at 3:00 p.m. ET

Roth Capital Conference – Laguna Niguel, CA

Date: March 23, 2026

Participation: Investor meetings

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, visit Exagen.com or follow Exagen on LinkedIn.

Investors:
Tina Jacobsen, CFA
IR@exagen.com

FAQ

When will Exagen (XGN) present at the KeyBank Capital Markets Healthcare Forum in 2026?

Exagen will participate virtually on March 17, 2026, with a fireside chat at 3:00 p.m. ET. According to Exagen, management will hold investor meetings and present in a fireside chat during the virtual forum.

What is Exagen's (XGN) schedule for the Roth Capital Conference in March 2026?

Exagen will attend the Roth Capital Conference in Laguna Niguel on March 23, 2026 for investor meetings. According to Exagen, management plans one-on-one investor meetings at the Laguna Niguel event on that date.

How can investors access Exagen's (XGN) KeyBank virtual fireside chat on March 17, 2026?

Investors should register for the KeyBank virtual forum to access the fireside chat at 3:00 p.m. ET on March 17, 2026. According to Exagen, participation is via the KeyBank Capital Markets Healthcare Forum virtual platform.

Who from Exagen (XGN) will participate in the March 2026 investor conferences?

Company management will represent Exagen at both events, participating in investor meetings and a fireside chat. According to Exagen, management will lead meetings at the Roth conference and the virtual KeyBank forum.

Will Exagen (XGN) hold investor meetings during both March 2026 events?

Yes, Exagen management will conduct investor meetings at both the KeyBank virtual forum on March 17, 2026 and the Roth Capital Conference on March 23, 2026. According to Exagen, investor meetings are confirmed for both dates.